159 related articles for article (PubMed ID: 26215394)
81. The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons.
Fragkoudis R; Breakwell L; McKimmie C; Boyd A; Barry G; Kohl A; Merits A; Fazakerley JK
J Gen Virol; 2007 Dec; 88(Pt 12):3373-3384. PubMed ID: 18024907
[TBL] [Abstract][Full Text] [Related]
82. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma.
Suter SE; Chein MB; von Messling V; Yip B; Cattaneo R; Vernau W; Madewell BR; London CA
Clin Cancer Res; 2005 Feb; 11(4):1579-87. PubMed ID: 15746063
[TBL] [Abstract][Full Text] [Related]
83. An antiviral substance from Penicillium funiculosum. II. Effect of helenine upon infection in mice with Semliki Forest virus.
SHOPE RE
J Exp Med; 1953 May; 97(5):627-38. PubMed ID: 13052823
[TBL] [Abstract][Full Text] [Related]
84. A DOG TEST FOR MEASURING THE IMMUNIZING POTENCY OF ANTIRABIES VACCINES.
Webster LT; Casals J
J Exp Med; 1940 Apr; 71(5):719-30. PubMed ID: 19870993
[TBL] [Abstract][Full Text] [Related]
85. AN IMMUNIZING SUBSTANCE FOR SEMLIKI FOREST VIRUS IN THE LIVERS OF IMMUNE MICE : I. THE INITIAL OBSERVATION TOGETHER WITH A CONSIDERATION OF THE ATTENDING CONDITIONS.
Shope RE
J Exp Med; 1961 Feb; 113(3):511-5. PubMed ID: 19867188
[TBL] [Abstract][Full Text] [Related]
86. Semliki Forest Virus.
Manwaring WH
Cal West Med; 1945 Jan; 62(1):4. PubMed ID: 18746959
[No Abstract] [Full Text] [Related]
87. Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.
Taipale K; Liikanen I; Juhila J; Turkki R; Tähtinen S; Kankainen M; Vassilev L; Ristimäki A; Koski A; Kanerva A; Diaconu I; Cerullo V; Vähä-Koskela M; Oksanen M; Linder N; Joensuu T; Lundin J; Hemminki A
Mol Ther; 2016 Feb; 24(1):175-83. PubMed ID: 26310629
[TBL] [Abstract][Full Text] [Related]
88. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.
Herrador-Cañete G; Zalacain M; Labiano S; Laspidea V; Puigdelloses M; Marrodan L; Garcia-Moure M; Gonzalez-Huarriz M; Marco-Sanz J; Ausejo-Mauleon I; de la Nava D; Hernández-Osuna R; Martínez-García J; Silva-Pilipich N; Gurucega E; Patiño-García A; Hernández-Alcoceba R; Smerdou C; Alonso MM
Mol Ther Oncolytics; 2022 Sep; 26():246-264. PubMed ID: 35949950
[TBL] [Abstract][Full Text] [Related]
89. Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.
Béguin J; Nourtier V; Gantzer M; Cochin S; Foloppe J; Balloul JM; Laloy E; Tierny D; Klonjkowski B; Quemeneur E; Maurey C; Erbs P
BMC Vet Res; 2020 Aug; 16(1):307. PubMed ID: 32843040
[TBL] [Abstract][Full Text] [Related]
90. Oncolytic Viruses for Canine Cancer Treatment.
Sánchez D; Cesarman-Maus G; Amador-Molina A; Lizano M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30373251
[TBL] [Abstract][Full Text] [Related]
91. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.
MacNeill AL; Weishaar KM; Séguin B; Powers BE
Viruses; 2018 Jul; 10(8):. PubMed ID: 30060548
[TBL] [Abstract][Full Text] [Related]
92. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.
Lundstrom K
Biologics; 2018; 12():43-60. PubMed ID: 29445265
[TBL] [Abstract][Full Text] [Related]
93. Oncolytic Alphaviruses in Cancer Immunotherapy.
Lundstrom K
Vaccines (Basel); 2017 Apr; 5(2):. PubMed ID: 28417936
[TBL] [Abstract][Full Text] [Related]
94. Pseudo-typed Semliki Forest virus delivers EGFP into neurons.
Jia F; Miao H; Zhu X; Xu F
J Neurovirol; 2017 Apr; 23(2):205-215. PubMed ID: 27739033
[TBL] [Abstract][Full Text] [Related]
95. On the potential of oncolytic virotherapy for the treatment of canine cancers.
MacNeill AL
Oncolytic Virother; 2015; 4():95-107. PubMed ID: 27512674
[TBL] [Abstract][Full Text] [Related]
96. Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.
Autio KP; Ruotsalainen JJ; Anttila MO; Niittykoski M; Waris M; Hemminki A; Vähä-Koskela MJ; Hinkkanen AE
BMC Vet Res; 2015 Jul; 11():170. PubMed ID: 26215394
[TBL] [Abstract][Full Text] [Related]
97. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
[TBL] [Abstract][Full Text] [Related]
98. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
99. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
[TBL] [Abstract][Full Text] [Related]
100. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.
Määttä AM; Mäkinen K; Ketola A; Liimatainen T; Yongabi FN; Vähä-Koskela M; Pirinen R; Rautsi O; Pellinen R; Hinkkanen A; Wahlfors J
Int J Cancer; 2008 Oct; 123(7):1704-11. PubMed ID: 18651570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
